Emerging retatrutide, a twin -action medication targeting both GLP-1 and GIP receptors, is creating considerable excitement within the weight loss community. Initial clinical trials have revealed substantial losses in physical mass and gains in health markers for people with obesity . Scientists believe this ground-breaking approach could represent